WHO rules involve manufacturers to carry out a ongoing danger management method for sterility test isolators, such as regular hazard assessments and the event of risk-based mostly Manage procedures. Manufacturers wanting to apply these techniques must deliver sturdy validation information to show their equivalence to pharmacopoeial methods.